Company profile: Oxford Nanopore
1.1 - Company Overview
Company description
- Provider of electronics-based nanopore DNA/RNA sequencing technology used in more than 80 countries for biological research, including large-scale human genomics, cancer research, and microbiology. Portfolio includes devices from portable to ultra-high throughput: MinION, GridION, PromethION, the Flongle adapter, forthcoming SmidgION mobile device, and VolTRAX for automated sample and library preparation.
Products and services
- PromethION: A scalable nanopore sequencing system delivering ultra-high throughput, enabling large-scale human genomics and cancer research applications with efficient, continuous data generation
- GridION: A benchtop nanopore sequencing device engineered for higher throughput than MinION, suited to microbiology studies and efficient laboratory runs
- MinION: A portable nanopore DNA/RNA sequencing device offering real-time data analysis for on-the-spot runs, used worldwide across more than 80 countries
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Oxford Nanopore
Quantapore
HQ: United States
Website
- Description: Provider of nanopore-based analytical platforms for single-molecule analysis in proteomics and genomics and nanopore-based nucleic acid sequencing technology to advance research, drug discovery, and diagnostics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Quantapore company profile →
Cresilon
HQ: United States
Website
- Description: Provider of plant-based hemostatic gel solutions for trauma care, offering VETIGEL for veterinary use and Cresilon Hemostatic Gel (CHG) for human use. VETIGEL is biocompatible and stops bleeding in seconds; both gels work quickly without the need for manual pressure.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cresilon company profile →
N4 Pharma
HQ: United Kingdom
Website
- Description: Provider of drug reformulation solutions, developing and out-licensing new versions of existing and novel high-value drugs for unmet needs. Advances products to clinical proof of concept then partners for regulatory. Offerings include Nuvec, a silica nanoparticle system to protect and deliver siRNA, RNA, and DNA; LipTide, a lipid and peptide-based platform that mimics a natural virus for targeted RNA delivery; and ECP105, an siRNA therapy for post-surgical glaucoma by silencing MRTF-B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full N4 Pharma company profile →
Arcturus Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage mRNA medicines and vaccines, including ARCT-154, a self-amplifying mRNA COVID-19 vaccine approved for use in adults; investigational therapies ARCT-032 and LUNAR-CF for cystic fibrosis and LUNAR-OTC for ornithine transcarbamylase deficiency; and platforms STARR™ mRNA Technology and LUNAR® lipid-mediated delivery for nucleic acid drug delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arcturus Therapeutics company profile →
Blueberry Therapeutics
HQ: United Kingdom
Website
- Description: Provider of nanomedicine-enabled topical treatments for dermatological conditions, including antifungal sprays BB2603 for onychomycosis and BB1202 for tinea pedis that enhance drug penetration with lower doses, and BB1511 cream for atopic dermatitis to support skin barrier and reduce inflammation; also conducts clinical trials to test safety and efficacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Blueberry Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Oxford Nanopore
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Oxford Nanopore
2.2 - Growth funds investing in similar companies to Oxford Nanopore
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Oxford Nanopore
4.2 - Public trading comparable groups for Oxford Nanopore
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →